Indications

It is indicated for correcting the disorder of coagulation due to deficiency of human coagulation Factor Ⅷ , mainly for prevention andcontrol of bleeding in patients with hemophilia A or acquired Factor Ⅷ deficiency, and for treatment of bleeding caused by operation of these patients. 

Highlights

1. A kind of concentrated preparation, rich in vWF, is closer to FVIII in human plasma; 

2. High quality and safety of plasma;

3. Without preservatives and antibiotics, have high purity and good stability;
4. Standardized system certification which conform to international standard.

Administration

It should be administered intravenously only, and the course of administration should be strictly monitored by the physician. If the product is just brought out from the refrigerator or at the low temperature in winters, it must be warmed up to 25 - 37 ℃ for dissolution.

Otherwise, precipitation will likely appear.

Sterile Water for Injection or 5% dextrose should beinfused into the vial at the label-indicated volume. 

Then the vial should be swirled gently to dissolve the product and avoid any foam. 

After that, atransfusion syringe with filter is used for intravenous injection. The infusion usually is conducted at a rate of 60 drops per minute. 

After dissolution, the product should be used out within one hour without any delay. 

Do not refrigerate the reconstituted solution. Discard all administration equipment after use.